## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.0% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($97.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Medtronic PLC $MDT Position Reduced by Panagora Asset Management Inc.**
- Source: MarketBeat | 20251202T123125 | Somewhat-Bullish | Relevance: 100%
- Panagora Asset Management Inc. significantly reduced its stake in Medtronic PLC by 2.7% in the second quarter of 2025. Despite this reduction, Medtronic reported strong quarterly earnings, beating analyst expectations with an EPS of $1.36 and revenue of $8.96 billion. The medical technology company also provided positive FY2026 EPS guidance, and analysts maintain a "Moderate Buy" rating for the stock.

**2. Quadrant Capital Group LLC Purchases 3,267 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251201T112259 | Bullish | Relevance: 99%
- Quadrant Capital Group LLC increased its stake in Medtronic PLC by 27.4%, acquiring an additional 3,267 shares to bring its total to 15,185 shares valued at approximately $1.32 million. Concurrently, Medtronic EVP Harry Skip Kiil sold 8,605 shares, reducing his position by 19.46%. The company reported strong quarterly earnings, beating expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $110.44.

**3. Grantham Mayo Van Otterloo & Co. LLC Trims Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20251201T100242 | Somewhat-Bullish | Relevance: 99%
- Grantham Mayo Van Otterloo & Co. LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 60% in the second quarter, selling over 101,000 shares. This comes even as Medtronic reported solid quarterly results, beating EPS and revenue estimates, and provided positive FY2026 guidance. Insider selling also occurred, with EVP Harry Skip Kiil trimming his holdings, while institutional investors collectively own a substantial portion of the company's stock.

**4. Trustmark Bank Trust Department Reduces Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251202T122135 | Somewhat-Bullish | Relevance: 99%
- Trustmark Bank Trust Department significantly reduced its stake in Medtronic PLC by 33.3% in Q2 2025, selling 7,136 shares. This move comes as Medtronic reports strong quarterly earnings, beating analyst estimates, and provides optimistic FY2026 guidance, alongside a "Moderate Buy" consensus rating from analysts.

**5. Medtronic welcomes Dr. Gerald Denny as Chief Medical Officer for Acute Care & Monitoring**
- Source: Medtronic | 20251202T135143 | Bullish | Relevance: 98%
- Medtronic announced the appointment of Dr. Gerald "Jeb" Denny as Chief Medical Officer for its Acute Care & Monitoring (ACM) business. Dr. Denny brings extensive medical and product expertise from his previous roles at BD and MRIoA, aiming to strengthen ACMâ€™s medical strategy and deepen relationships with the healthcare community. He will continue to practice medicine part-time, ensuring he remains connected to clinical practice and innovation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.7x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $129.2B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.7 |
| Current P/E | 18.1 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.5% to -3.0% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.58), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.95% (CS: 23) | Weak |
| RSI_14 | 61.6 | Neutral |
| MACD Histogram | 0.58 | Bullish |
| vs SMA20 | 1.040x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $102.03
- **Stop Loss:** $97.99 (4.0% risk)
- **Target:** $106.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 247
- **Position Value:** $25,201.41
- **Portfolio %:** 25.20%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*